Articles tagged with Antibodies
Researchers found that breastfeeding provides an immune boost to infants, reducing the risk of respiratory infections such as pneumonia. However, milk also mounts responses to beneficial gut bacteria, which can be disruptive and increase the risk of gastrointestinal infections.
A recent study published in CANCER found that adults with hematologic malignancies mounted immune responses after a COVID-19 booster dose, with 56% of nonresponders producing antibodies. However, the initial vaccine showed limited effectiveness, with only 48% of patients developing detectable antibodies.
A team led by Dr. Johan Duchêne investigated commercial antibodies against ACKR1, refuting a previous study that claimed its expression on macrophages and monocytes. The study emphasizes the significance of antibody specificity and demonstrates the importance of publishing corrections in scientific research.
Scientists have found that prior exposure to Staphylococcus aureus prevents effective vaccination due to immune response memory. To overcome this, the research suggests targeting only the protective component of the protein IsdB, generating a more effective vaccine against MRSA.
A study found that Omicron's neutralization capacity outperforms its predecessors, even in vaccinated individuals. Antibody levels against ancestral SARS-CoV-2 are roughly 10 times higher in vaccinated people than those with natural immunity.
A new nanoparticle vaccine has shown promising results in protecting against a spectrum of COVID-19-causing variants and related viruses. The vaccine induces the production of cross-reactive antibodies that recognize virtually every SARS-like betacoronavirus strain, providing broad-spectrum protection against future pandemics.
Researchers at the Garvan Institute of Medical Research have identified key molecules linked to the mammalian-meat allergy caused by tick bites. The study reveals that a particular antibody type has a natural pocket into which a sugar molecule, galactose-α-1,3-galactose (alpha-gal), snugly fits.
Researchers at The University of Tokyo have created a new antibody-based method for detecting SARS-CoV-2 that does not require a blood sample. This innovative approach uses interstitial fluid from human skin to detect antibodies within 3 minutes.
Researchers at the German Primate Center found that emerging Omicron subvariants BA.2.12.1, BA.4, and BA.5 are inhibited less efficiently by existing therapeutic antibodies, which may reduce protection against future infections. The study suggests these variants have acquired biological traits allowing for more efficient transmission.
The study found that legislatures, rather than governors, played a crucial role in shaping data reporting practices. Standardized data collection protocols and comprehensive race and ethnicity data are essential for addressing health disparities and reducing information asymmetries.
A study examined maternal immune responses and antibody transfer from mother to fetus for different COVID-19 vaccines across pregnancy trimesters. mRNA vaccination induced higher levels and functions against SARS-CoV-2 variants, including Omicron, while first and third trimester vaccination led to enhanced maternal immune responses.
Researchers have developed a new therapeutic agent from Brazilian lapacho tree bark that targets acute myeloid leukemia cells while minimizing toxic effects on healthy cells. The compound is attached to an antibody that binds specifically to cancer cells, delivering the drug directly to its target.
A clinical trial found that interrupting treatment with methotrexate, a common immune-suppressing drug, doubles the antibody response to COVID-19 booster vaccinations in vulnerable individuals. This improvement is maintained over a 3-month period and has no adverse impact on quality of life.
A Brazilian patient with a rare genetic disease was treated with breast milk donated by a vaccinated woman, boosting her IgA levels and eliminating the virus. The treatment was successful after a week, with the patient testing negative twice at ten-day intervals.
A new study reveals that COVID-19 variants are formed in chronic patients with weakened immune systems, who experience prolonged infections. This leads to the accumulation of mutations, similar to those found in severe illness variants.
A new combination therapy using a plant virus and an antibody activates natural killer cells to target and destroy cancer cells. The therapy eliminates all tumors and prevents their recurrence, resulting in 100% survival in mouse models of colon cancer.
A UC San Diego study suggests COVID-19 rebound symptoms after taking Paxlovid are likely caused by insufficient drug exposure, not resistance or impaired immunity. The study found the virus remained sensitive to the drug and no relevant mutations were detected.
Researchers have developed a novel fusion protein that enables the detection of SARS-CoV-2 antibodies using widely available glucose meters. The test was validated on various patient samples and found to be as accurate as four different ELISAs.
Researchers developed a rapid blood assay that measures the magnitude and duration of immunity to SARS-CoV-2, allowing large-scale monitoring of population immunity. The test takes less than 24 hours to perform and is scalable to use broadly in the population.
A new preclinical study by Weill Cornell Medicine researchers shows that naturally-produced IgG antibodies in breast milk can protect infants from infection-induced diarrheal illness. These antibodies enhance infant immunity against bacterial pathogens causing gastrointestinal diseases.
A UVA researcher is using a harmless amoeba to develop an innovative treatment for deadly C. difficile infections in young children. The approach has the potential to deliver specific antibodies directly to the gut, reducing the need for antibiotics and addressing a growing public health threat.
A third dose of COVID-19 vaccine may be essential for kidney transplant patients in Japan to prevent severe disease and infection. Researchers found that only a third of patients developed sufficient antibodies after two doses, highlighting the need for additional protection.
A study published in Brain, Behaviour and Immunity found that lower neighbourhood cohesion is associated with a lower response to COVID-19 vaccines. Social cohesion was also linked to feelings of loneliness, which reduced the antibody response.
Researchers have developed a new tool to visualize leukocytes in the brain vasculature during in vivo two-photon laser scanning microscopy. The tool uses a fluorescent antibody targeting CD45, a ubiquitously expressed protein on white blood cells, allowing for tracking of circulating leukocytes over time and space.
A Brazilian group developed a peptide called Rb4 that triggers necrosis in murine melanoma cells and inhibits the viability of human cancer cells. In mice, Rb4 reduced lung metastasis and slowed subcutaneous melanoma growth, increasing survival by 25%.
A study of 50 people found that higher body weights were inversely correlated with anti-SARS-CoV-2 antibody levels six months after receiving two doses of the Pfizer/BioNTech COVID-19 vaccine. The findings suggest that weight may impact immune response to the vaccine.
Studies found people infected and vaccinated had similarly robust antibody responses against variants alpha through omicron; Immune memory cells against common cold coronaviruses may be markers of longer immunity. Researchers hope to improve vaccines with these insights.
A new study analyzing 8 cohorts of COVID-19 patients found that antibody responses in previously infected individuals were relatively stable, providing protection from reinfection unless the new infection was the Omicron variant. Vaccination also boosted protection, with rapid immune responses observed even after a single vaccine dose.
A recent study reveals that nearly half of SARS-CoV-2 variants contain the same three mutations, which together improve the virus's ability to infect human cells and evade the immune system. The combination of K417, E484, and N501 mutations enhances viral fitness by balancing positive and negative selection pressures.
A new combination therapy using a tumor-suppressing lipid molecule and an antibody for cytotoxic T-lymphocyte antigen 4 has been shown to significantly slow tumor growth and enhance the strength of tumor-attacking T cells in liver cancer. This promising approach offers hope for patients with limited treatment options.
A new study by Gladstone Institutes and UC San Francisco found that infection with the Omicron variant provides weak immune response in unvaccinated individuals, failing to confer broad protection against other variants. In contrast, vaccinated individuals show stronger immunity against multiple COVID-19 strains.
Researchers compared SARS-CoV-2 antibody titers after Pfizer-BioNTech and Moderna COVID-19 vaccines in immunosuppressed patients. The study found differing antibody responses among these individuals, who have decreased immune responses to standard vaccines.
Researchers found that a single mRNA vaccine booster shot can provide the same level of protection as three doses, making it a promising investment for resource-poor countries. The study suggests that this strategy could benefit billions of people worldwide and help combat emerging COVID-19 variants.
Researchers found that MS patients treated with Rituximab who have higher B cell counts of 40/µL or more develop protective levels of antibodies after vaccination. This suggests that measuring B cell level before vaccination is crucial for increasing the chance of a positive response.
Researchers discovered that memory B cells produce non-specific antibodies to combat virus mutants, working alongside phagocytes to screen for variants. This mechanism may offer protection against SARS-CoV2 and HIV variants, and could influence vaccine development.
Researchers developed a new test method to detect tuberculosis (TB) progression from latent infection in elephants using IgG antibodies against Antigen 85B. High levels of IgG against ESAT6/CFP10 remained constant, while IgG against Ag85B increased before disease onset and declined with treatment.
Scripps Research scientists found that COVID-19 patients develop more robust antibodies against coronaviruses causing common colds and SARS-CoV-1 and MERS-CoV. This increased antibody response may lead to improved vaccine development, targeting a broader range of viruses.
A recent study presented at the 2022 ARRS Annual Meeting found that COVID-19 infection significantly impacted lung cancer screening in diverse inner-city populations. The research revealed that approximately 9% of participants developed COVID-19 during the pandemic, with mortality rates reaching 6.9%.
Researchers at the Medical University of South Carolina have developed a highly accurate and minimally invasive test for detecting liver fibrosis. The test, GlycoFibroTyper, measures changes in sugar molecules attached to antibodies in patient blood samples.
Researchers from IRB Barcelona and Merus have discovered MCLA-158, a bi-specific antibody targeting cancer stem cells. The treatment prevents metastasis and slows primary tumor growth in experimental models of cancer.
Research found that 3.4% of pregnant women who caught COVID-19 passed antibodies to their babies, providing some protection. However, these antibodies gradually decrease over time and disappear within 100 days after birth.
A new study from the University of Illinois at Urbana-Champaign has developed a machine-learning model that can predict which pathogens antibodies will target, with an accuracy rate of over 85%. The model uses genetic sequences of antibodies to differentiate between influenza and SARS-CoV-2.
Researchers at Gwangju Institute of Science and Technology (GIST) have developed a new technique to easily visualize viruses using an optical microscope, called the Gires-Tournois immunoassay platform. The platform uses 'slow light' technology to detect coronavirus particles by slowing down light that gets reflected around them.
Researchers have developed a new treatment for chronic inflammation by targeting the ASC protein with nanobodies, which can dissolve harmful molecular complexes and counteract inflammation. The treatment has shown promising results in mouse models, alleviating symptoms of rheumatoid arthritis and gout.
Researchers at Karolinska Institutet study how the immune system protects against malaria, finding that people who have contracted the disease before develop a tolerance that prevents severe disease. This knowledge can aid in the development of more effective vaccines.
Researchers at Charité, MDC, and FU Berlin have studied the mechanisms of action of antibody and dexamethasone treatments for COVID-19. They found that combination therapy is more effective in reducing viral activity and inflammation in lung tissue, suggesting a potential game-changer in treating severe cases.
A recent study found that the Omicron variant is associated with a significant increase in breakthrough infections among cancer patients, especially those undergoing treatment. Protective measures and vaccine adaptations are crucial to mitigate this risk.
Researchers developed a new treatment option for relapsed or refractory CD30+ lymphoma using natural killer cells complexed with a CD30/CD16A bispecific antibody. The treatment showed an overall response rate of 89% in patients with advanced lymphoma.
A new biodegradable gel has been developed to improve the immune system's ability to combat cancer. The gel releases drugs and special antibodies that target tumor cells, slowing their growth and increasing the lifespan of mice. This breakthrough could lead to new clinical trials for human patients in the coming years.
A third dose of COVID-19 vaccine significantly increases immune responses in patients with multiple myeloma, but a subset remains vulnerable. The study found that 88% of patients developed antibodies after the third dose, leading to improved neutralization of the wild-type virus.
The newly developed COVID vaccine, PreS-RBD, targets the receptor binding domains of SARS-CoV-2 and induces a robust immune response. The vaccine has shown effectiveness in protecting against all known SARS-CoV-2 variants, including omicron, even in individuals who have not previously built up immunity.
Researchers found that prior infection with common human coronaviruses does not provide immunity against SARS-CoV-2 due to limited cross-reactive antibodies. This suggests no significant adverse effects from antibody-dependent enhancement, reducing the risk of COVID-19 complications.
Researchers found that older killifish have less diverse circulating antibodies compared to younger fish, contributing to reduced immune function. This decrease in antibody diversity may lead to a reduced ability to respond to infections.
Researchers at Karolinska Institutet in Sweden have developed a novel strategy to identify potent miniature antibodies, so-called nanobodies, against emerging SARS-CoV-2 variants. The approach led to the discovery of multiple nanobodies that effectively blocked infection with different SARS-CoV-2 variants.
Researchers at Kobe University discover that immobilization induces loss of muscle mass by disrupting calcium levels and triggering the KLF15-IL-6 pathway. This finding may lead to the development of a treatment for muscle loss, known as sarcopenia, which affects aging societies.
A University of Gothenburg study found that IgA antibodies present in the respiratory tract protected healthcare workers from contracting COVID-19. The research, published in the European Journal of Immunology, suggests that these antibodies may play a crucial role in preventing severe illness and hospitalization.
A team of Canadian scientists developed a scalable serology assay to track COVID-19 antibodies, informing public health decisions and vaccine timing. The assay has been used in over 30 studies across Canada, capturing natural infection and vaccination responses with high accuracy.
A booster dose of the Pfizer/BioNTech vaccine significantly increases antibodies against SARS-CoV-2, reversing a drop in immunity after two doses. In subjects given CoronaVac or Oxford-AstraZeneca vaccines, the booster raised immunity by a factor of 25 and 7, respectively.
Researchers at Max Planck Institute of Molecular Physiology discovered that vaccination after COVID-19 recovery increases neutralizing antibody levels by up to five times, providing better protection against current coronavirus variants. The study involved 140 volunteers and showed that antibody levels remained high even after 300 days.
Children previously infected with COVID-19 develop long-lasting natural circulating antibodies that provide immunity. The study's findings suggest that these antibodies can last for at least seven months and do not differ by age, weight, or severity of symptoms.